Table 3. Clinicopathologic characteristics according to mutational status of each gene.
| KRAS mutation | BRAF mutation | PIK3CA mutation | HER2 amplification | MSI status | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Characteristic | Total | Mutant type | P | Mutant type | P | Mutant type | P | Positive | P | MSI-H | P |
| Age | 0.503 | 0.676 | 0.347 | 0.081 | 0.131 | ||||||
| Mean ± SD | 60.32 ± 11.64 | 61.83 ± 14.69 | 61.92 ± 10.16 | 54.69 ± 11.31 | 70.33 ± 5.51 | ||||||
| Sex | 0.752 | 0.688* | 0.130 | 0.742 | 0.596* | ||||||
| Male | 103 | 55 (53.4%) | 4 (3.9%) | 17 (16.5%) | 8 (7.8%) | 1 (1.0%) | |||||
| Female | 88 | 49 (55.7%) | 2 (2.3%) | 8 (9.1%) | 8 (9.1%) | 2 (2.3%) | |||||
| Location | 0.021 | 0.127* | 0.282 | 0.006* | 0.262* | ||||||
| Right | 49 | 35 (71.4%) | 4 (8.2%) | 9 (18.4%) | 2 (4.1%) | 2 (4.1%) | |||||
| Left | 71 | 35 (49.3%) | 1 (1.4%) | 10 (14.1%) | 2 (2.8%) | 1 (1.4%) | |||||
| Rectum | 71 | 34 (47.9%) | 1 (1.4%) | 6 (8.5%) | 12 (16.9%) | 0 (0%) | |||||
| Histologic grade | 0.029 | 0.189* | 0.538* | 0.242* | 0.357* | ||||||
| Low | 165 | 95 (57.6%) | 4 (2.4%) | 23 (13.9%) | 12 (7.3%) | 2 (1.2%) | |||||
| High | 26 | 9 (34.6%) | 2 (7.7%) | 2 (7.7%) | 4 (15.4%) | 1 (3.8%) | |||||
| T stage | 0.833 | 0.033* | 0.563 | 0.520 | 0.561* | ||||||
| T1-T3 | 117 | 63 (53.8%) | 1 (0.9%) | 14 (12.0%) | 11 (9.4%) | 1 (0.9%) | |||||
| T4 | 74 | 41(55.4%) | 5 (6.8%) | 11 (14.9%) | 5 (6.8%) | 2 (2.7%) | |||||
| pTNM stage† | 0.179* | 1.000* | 0.422* | 0.306* | 0.224* | ||||||
| I- | 2 | 1 (50.0%) | 1 (50%) | 0 (0%) | 0 (0%) | 0 (0%) | |||||
| II | 19 | 7 (52.9%) | 0 (0%) | 4 (21.1%) | 1 (5.3%) | 0 (0%) | |||||
| III | 43 | 28 (65.1%) | 1 (2.3%) | 3 (7.0%) | 1 (2.3%) | 2 (4.7%) | |||||
| IV | 127 | 68 (53.5%) | 5 (3.9%) | 18 (14.2%) | 14 (11.0%) | 1 (0.8%) | |||||
| Lymphatic invasion | 0.622 | 0.097* | 0.499 | 0.806 | 1.000* | ||||||
| Absent | 65 | 37 (56.9%) | 0 (0%) | 10 (15.4%) | 5 (7.7%) | 1 (1.5%) | |||||
| Present | 126 | 67 (53.2%) | 6 (4.8%) | 15 (11.9%) | 11 (8.7%) | 2 (1.6%) | |||||
| Venous invasion | 0.148 | 1.000* | 0.458 | 0.780* | 1.000* | ||||||
| Absent | 133 | 77 (57.9%) | 4 (3.0%) | 19 (14.3%) | 12 (9.0%) | 2 (1.5%) | |||||
| Present | 58 | 27 (46.6%) | 2 (3.4%) | 6 (10.3%) | 4 (6.9%) | 1 (1.7%) | |||||
| Perineural invasion | 0.896 | 0.685* | 0.640 | 0.844 | 1.000* | ||||||
| Absent | 91 | 50 (54.9%) | 2 (2.2%) | 13 (14.3%) | 8 (8.8%) | 1 (1.1%) | |||||
| Present | 100 | 54 (54.0%) | 4 (4.0%) | 12 (12.0%) | 8 (8.0%) | 2 (2.0%) | |||||
KRAS, Kirsten rat sarcoma viral oncogene homolog; BRAF, v-raf murine sarcoma viral oncogene homolog B1; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha; HER2, human epidermal growth factor receptor 2; MSS, microsatellite stable; MSI-L, microsatellite instability-low; MSI-H, microsatellite instability-high; SD, standard deviation
Age was compared between two groups by using independent T test.
*P-values are calculated by using Fisher’s exact test because less than 80% of the cells have an expected frequency of 5 or greater, or any cell has an expected frequency smaller than 1.0.
†Stage is the stage at initial diagnosis.